Skip to content

Opus Genetics IRD Professional service fees

Professional service fees at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's professional service fees?
Opus Genetics (IRD) reported professional service fees of $1.25M in Q1 2026.
How has Opus Genetics's professional service fees changed year-over-year?
Opus Genetics's professional service fees decreased by 69.3% year-over-year, from $4.07M to $1.25M.
What is the long-term trend for Opus Genetics's professional service fees?
Over 5 years (2020 to 2025), Opus Genetics's professional service fees has grown at a 17.7% compound annual growth rate (CAGR), from $186K to $420K.